Quoin Pharmaceuticals (NASDAQ:QNRX) Posts Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Quoin Pharmaceuticals (NASDAQ:QNRX) issued its quarterly earnings results on Thursday. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.15, Zacks reports.

Quoin Pharmaceuticals Stock Up 2.0 %

Shares of Quoin Pharmaceuticals stock opened at $0.30 on Thursday. The business’s fifty day simple moving average is $0.41 and its 200-day simple moving average is $0.56. Quoin Pharmaceuticals has a 52 week low of $0.27 and a 52 week high of $1.57. The firm has a market cap of $1.53 million, a PE ratio of -0.07 and a beta of 1.82.

Insiders Place Their Bets

In related news, CFO Gordon Dunn acquired 122,221 shares of the stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average price of $0.45 per share, with a total value of $54,999.45. Following the transaction, the chief financial officer now owns 151,077 shares of the company’s stock, valued at approximately $67,984.65. This trade represents a 423.55 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Denise P. Carter bought 555,556 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The stock was bought at an average price of $0.45 per share, with a total value of $250,000.20. Following the acquisition, the chief operating officer now directly owns 602,648 shares in the company, valued at $271,191.60. The trade was a 1,179.72 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 777,777 shares of company stock valued at $350,000 over the last 90 days. 3.70% of the stock is owned by company insiders.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.